CareCloud, Inc. (CCLD) - Q2 2024 10-Q Summary
Business Context and Reporting Period
CareCloud, Inc. is a healthcare information technology company providing technology-enabled revenue cycle management (RCM), cloud-based software (SaaS), and medical practice management services. The company operates through two segments: Healthcare IT and Medical Practice Management. This report covers the quarterly period ended June 30, 2024.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Q2 2023 (3 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $28.1 million | $54.1 million | $29.4 million | $59.4 million |
| Operating Income | $2.3 million | $2.4 million | ($1.3 million) Loss | ($1.5 million) Loss |
| Net Income | $1.7 million | $1.4 million | ($1.8 million) Loss | ($2.2 million) Loss |
| Net Loss Attributable to Common Shareholders | ($2.2 million) | ($3.8 million) | ($5.7 million) | ($10.1 million) |
| Cash and Cash Equivalents | $2.6 million (End of Period) | Working Capital: $0.7 million (Positive) | ||
| Debt (Line of Credit) | $5.0 million outstanding | Unused borrowing base: ~$10.7 million | ||
| Adjusted EBITDA | $6.4 million | $10.1 million | $3.8 million | $8.1 million |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 4% in Q2 and 9% YTD compared to 2023. The decline was primarily driven by a reduction in project-based professional services and the wind-down of two large acquired accounts that transitioned to their acquirers' systems.
- Profitability Improvement: The company returned to GAAP operating income and net income in Q2 2024, reversing losses from the same period in 2023. This was achieved through significant cost reductions.
- Expense Reduction: Total operating expenses decreased 16% in Q2 and 15% YTD. Direct operating costs fell 13% (Q2) and 15% (YTD) due to headcount reductions in the U.S. and Pakistan. Selling and marketing expenses dropped 36% (Q2) and 34% (YTD).
- Amortization Increase: Amortization expense increased 13% (Q2) and 23% (YTD) due to the placement of additional internal-use software into production.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: Management believes substantial doubt regarding the company's ability to continue as a going concern has been alleviated. This is due to a restructuring plan implemented in 2023 (targeting ~$22 million in annualized cost savings) and the suspension of preferred stock dividends (saving ~$1.3 million/month).
- Preferred Stock Dividends: Monthly cash dividends for Series A and Series B Preferred Stock remain suspended since December 2023. Approximately $7.1 million in dividends are currently in arrears.
- Change Healthcare Incident: The company utilized alternative platforms to resume claims submission following the Change Healthcare cybersecurity incident in February 2024. Management determined the incident did not materially impact Q2 financial results, though cash flow impacts were recognized in Q1.
- Restructuring: The company continues to incur restructuring costs related to workforce optimization. Approximately $0.4 million was incurred in the first six months of 2024.
- Restatement: The company restated its Q1 2024 results to include an earned but undeclared preferred stock dividend of approximately $1.3 million for March 2024, which increased the net loss attributable to common shareholders for that quarter.
Investor Verification Checklist
- Dividend Arrears: Verify the total accumulated preferred stock dividends in arrears (~$7.1 million) and the conditions required to resume payments.
- Revenue Concentration: Assess the impact of the loss of the two large accounts mentioned in the MD&A on future revenue stability.
- Debt Covenants: Confirm continued compliance with the Silicon Valley Bank (First Citizens Bank) credit agreement covenants, specifically the minimum liquidity ratio and adjusted EBITDA requirements.
- Offshore Operations: Review risks associated with offshore operations in Pakistan and Sri Lanka, including currency fluctuations and regulatory changes.
- Goodwill Valuation: Monitor stock price performance, as a significant decline could trigger another goodwill impairment test for the Healthcare IT segment.